TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 06/21/23

2023-06-21 05:10:17 ET Summary Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manu...

2023-06-21 02:47:25 ET Summary Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well as promise in its pipeline and geographic diversif...

2023-05-16 01:29:25 ET Summary GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to Fluarix and FluLaval, which regulators approved t...

2023-05-11 22:42:09 ET Takeda Pharmaceutical Company Limited (TAK) Q4 2022 Results Conference Call May 11, 2023 06:00 AM ET Company Participants Christopher O’Reilly - Global Head of IR & Global Finance Christophe Weber - President, CEO & Representativ...

2023-05-01 23:53:08 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Arrowhead Pharmaceuticals and Meta propelled my portfolio again to all-time highs and mar...

2023-04-03 04:12:14 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Bitcoin, AMD, and Meta propelled my portfolio to all-time highs and market-beating return...

2023-04-03 03:51:40 ET Summary Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on...

2023-03-30 11:28:34 ET A phase 4 study of Takeda Pharmaceutical Co.'s ( NYSE: TAK ) Entyvio met its primary endpoint in patients with ulcerative colitis. Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis ...

2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...